The figures below visualize diagnostic-performance and epidemiologic points emphasized by the paper and placed in recent context (noted citations inline).
Bryan & McAdam (2015) is a high-quality, clinically focused review (useful score: see metrics below) that accurately summarizes knowledge through 2014β2015: Stx biology, clinical risks (HUS), epidemiology (O157 dominance yet rise of non-O157), and diagnostic strategies. Its main limitation is temporal: genomic-resolution surveillance, validated serogroup markers, and routine multiplex NAAT/WGS workflows developed after 2015 materially expand diagnostic and epidemiologic capabilities beyond what the review could cover (see genomic and pangenome studies cited). Labs and policymakers should combine the review's practical lab recommendations with modern WGS/targeted-marker approaches for outbreak resolution and serogroup tracking
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.